{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:06:25Z","timestamp":1793286385193,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011002","name":"National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund","doi-asserted-by":"publisher","award":["U1802284"],"award-info":[{"award-number":["U1802284"]}],"id":[{"id":"10.13039\/501100011002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071847"],"award-info":[{"award-number":["82071847"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971548"],"award-info":[{"award-number":["81971548"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82151218"],"award-info":[{"award-number":["82151218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92169112"],"award-info":[{"award-number":["92169112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172287"],"award-info":[{"award-number":["82172287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emerging SARS-CoV-2 variants, commonly with many mutations in S1 subunit of spike (S) protein are weakening the efficacy of the current vaccines and antibody therapeutics. This calls for the variant-proof SARS-CoV-2 vaccines targeting the more conserved regions in S protein. Here, we designed a recombinant subunit vaccine, HR121, targeting the conserved HR1 domain in S2 subunit of S protein. HR121 consisting of HR1\u2013linker1\u2013HR2\u2013linker2\u2013HR1, is conformationally and functionally analogous to the HR1 domain present in the fusion intermediate conformation of S2 subunit. Immunization with HR121 in rabbits and rhesus macaques elicited highly potent cross-neutralizing antibodies against SARS-CoV-2 and its variants, particularly Omicron sublineages. Vaccination with HR121 achieved near-full protections against prototype SARS-CoV-2 infection in hACE2 transgenic mice, Syrian golden hamsters and rhesus macaques, and effective protection against Omicron BA.2 infection in Syrian golden hamsters. This study demonstrates that HR121 is a promising candidate of variant-proof SARS-CoV-2 vaccine with a novel conserved target in the S2 subunit for application against current and future SARS-CoV-2 variants.<\/jats:p>","DOI":"10.1038\/s41422-022-00746-3","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T16:05:39Z","timestamp":1668096339000},"page":"1068-1085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein"],"prefix":"10.1038","volume":"32","author":[{"given":"Wei","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Fa","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Xian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Xuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Jiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Hua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Meng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Qi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Cui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-7135","authenticated-orcid":false,"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-1524","authenticated-orcid":false,"given":"Songying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-0324","authenticated-orcid":false,"given":"Yong-Tang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"746_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626\u2013636 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"746_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1126\/science.abm4915","volume":"375","author":"K Koelle","year":"2022","unstructured":"Koelle, K., Martin, M. A., Antia, R., Lopman, B. & Dean, N. E. The changing epidemiology of SARS-CoV-2. Science 375, 1116\u20131121 (2022).","journal-title":"Science"},{"key":"746_CR3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","volume":"28","author":"H Tegally","year":"2022","unstructured":"Tegally, H. et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. 28, 1785\u20131790 (2022).","journal-title":"Nat. Med."},{"key":"746_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/d41573-022-00074-6","volume":"21","author":"E Dolgin","year":"2022","unstructured":"Dolgin, E. Pan-coronavirus vaccine pipeline takes form. Nat. Rev. Drug Discov. 21, 324\u2013326 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"746_CR5","doi-asserted-by":"publisher","first-page":"eabq0839","DOI":"10.1126\/science.abq0839","volume":"377","author":"AA Cohen","year":"2022","unstructured":"Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).","journal-title":"Science"},{"key":"746_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3\u201320 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"746_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572\u2013577 (2020).","journal-title":"Nature"},{"key":"746_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382.e17 (2020).","journal-title":"Cell"},{"key":"746_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","volume":"53","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315\u20131330.e9 (2020).","journal-title":"Immunity"},{"key":"746_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","volume":"5","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct. Target Ther. 5, 282 (2020).","journal-title":"Signal Transduct. Target Ther"},{"key":"746_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73\u201382 (2021).","journal-title":"Nat. Rev. Immunol"},{"key":"746_CR12","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728\u20131744.e16 (2022).","journal-title":"Cell"},{"key":"746_CR13","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","volume":"185","author":"K Xu","year":"2022","unstructured":"Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265\u20132278.e14 (2022).","journal-title":"Cell"},{"key":"746_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol"},{"key":"746_CR15","doi-asserted-by":"publisher","first-page":"701501","DOI":"10.3389\/fimmu.2021.701501","volume":"12","author":"D Mart\u00ednez-Flores","year":"2021","unstructured":"Mart\u00ednez-Flores, D. et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front. Immunol. 12, 701501 (2021).","journal-title":"Front. Immunol."},{"key":"746_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","volume":"399","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234\u2013236 (2021).","journal-title":"Lancet"},{"key":"746_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carre\u00f1o","year":"2021","unstructured":"Carre\u00f1o, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682\u2013688 (2021).","journal-title":"Nature"},{"key":"746_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"746_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185, 447\u2013456.e11 (2022).","journal-title":"Cell"},{"key":"746_CR20","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"746_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJMc2206576","volume":"387","author":"NP Hachmann","year":"2022","unstructured":"Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 387, 86\u201388 (2022).","journal-title":"N. Engl. J. Med."},{"key":"746_CR22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41591-021-01575-4","volume":"27","author":"M Levine-Tiefenbrun","year":"2021","unstructured":"Levine-Tiefenbrun, M. et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat. Med. 27, 2108\u20132110 (2021).","journal-title":"Nat. Med."},{"key":"746_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","volume":"399","author":"C Kuhlmann","year":"2022","unstructured":"Kuhlmann, C. et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 399, 625\u2013626 (2022).","journal-title":"Lancet"},{"key":"746_CR24","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.chom.2022.05.001","volume":"30","author":"J Ai","year":"2022","unstructured":"Ai, J. et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe 30, 1077\u20131083.e4 (2022).","journal-title":"Cell Host Microbe"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"746_CR26","doi-asserted-by":"publisher","first-page":"106698","DOI":"10.1016\/j.ijsu.2022.106698","volume":"103","author":"RK Mohapatra","year":"2022","unstructured":"Mohapatra, R. K. et al. The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic - Correspondence. Int. J. Surg. 103, 106698 (2022).","journal-title":"Int. J. Surg."},{"key":"746_CR27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"746_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abd4251","volume":"369","author":"Y Cai","year":"2020","unstructured":"Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 369, 1586\u20131592 (2020).","journal-title":"Science"},{"key":"746_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"746_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"746_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21968-w","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat. Commun. 12, 1715 (2021).","journal-title":"Nat. Commun."},{"key":"746_CR32","doi-asserted-by":"publisher","first-page":"eabc3539","DOI":"10.1126\/scitranslmed.abc3539","volume":"12","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran, S. et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci. Transl. Med. 12, eabc3539 (2020).","journal-title":"Sci. Transl. Med."},{"key":"746_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109\u20131116 (2021).","journal-title":"Science"},{"key":"746_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343\u2013355 (2020).","journal-title":"Cell Res"},{"key":"746_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev-cellbio-101512-122422","volume":"30","author":"B Podbilewicz","year":"2014","unstructured":"Podbilewicz, B. Virus and cell fusion mechanisms. Annu. Rev. Cell. Dev. Biol. 30, 111\u2013139 (2014).","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"key":"746_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/v12070693","volume":"12","author":"CT Barrett","year":"2020","unstructured":"Barrett, C. T. & Dutch, R. E. Viral membrane fusion and the transmembrane domain. Viruses 12, 693 (2020).","journal-title":"Viruses"},{"key":"746_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"F Li","year":"2016","unstructured":"Li, F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237\u2013261 (2016).","journal-title":"Annu. Rev. Virol."},{"key":"746_CR38","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","volume":"27","author":"B Chen","year":"2019","unstructured":"Chen, B. Molecular mechanism of HIV-1 entry. Trends Microbiol. 27, 878\u2013891 (2019).","journal-title":"Trends Microbiol"},{"key":"746_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/5584_2016_174","volume":"966","author":"ST Smrt","year":"2017","unstructured":"Smrt, S. T. & Lorieau, J. L. Membrane fusion and infection of the influenza hemagglutinin. Adv. Exp. Med. Biol. 966, 37\u201354 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"746_CR40","doi-asserted-by":"publisher","first-page":"eabk2226","DOI":"10.1126\/sciadv.abk2226","volume":"7","author":"SC Chiliveri","year":"2021","unstructured":"Chiliveri, S. C., Louis, J. M., Ghirlando, R. & Bax, A. Transient lipid-bound states of spike protein heptad repeats provide insights into SARS-CoV-2 membrane fusion. Sci. Adv. 7, eabk2226 (2021).","journal-title":"Sci. Adv"},{"key":"746_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41392-021-00698-x","volume":"6","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct. Target Ther. 6, 294 (2021).","journal-title":"Signal Transduct. Target Ther"},{"key":"746_CR42","doi-asserted-by":"publisher","first-page":"e00635","DOI":"10.1128\/JVI.00635-20","volume":"94","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y., Yu, D., Yan, H., Chong, H. & He, Y. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J. Virol. 94, e00635\u201320 (2020).","journal-title":"J. Virol."},{"key":"746_CR43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/22221751.2021.1917309","volume":"10","author":"D Yu","year":"2021","unstructured":"Yu, D. et al. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg. Microbes Infect. 10, 810\u2013821 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"746_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41422-022-00617-x","volume":"32","author":"S Xia","year":"2022","unstructured":"Xia, S. et al. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 32, 404\u2013406 (2022).","journal-title":"Cell Res."},{"key":"746_CR45","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1128\/JVI.76.13.6780-6790.2002","volume":"76","author":"H Golding","year":"2002","unstructured":"Golding, H. et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 76, 6780\u20136790 (2002).","journal-title":"J. Virol"},{"key":"746_CR46","doi-asserted-by":"publisher","first-page":"eaaz8822","DOI":"10.1126\/sciadv.aaz8822","volume":"6","author":"MA Benhaim","year":"2020","unstructured":"Benhaim, M. A. et al. Structural monitoring of a transient intermediate in the hemagglutinin fusion machinery on influenza virions. Sci. Adv. 6, eaaz8822 (2020).","journal-title":"Sci. Adv."},{"key":"746_CR47","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1126\/science.1057453","volume":"291","author":"MJ Root","year":"2001","unstructured":"Root, M. J., Kay, M. S. & Kim, P. S. Protein design of an HIV-1 entry inhibitor. Science 291, 884\u2013888 (2001).","journal-title":"Science"},{"key":"746_CR48","doi-asserted-by":"publisher","first-page":"14759","DOI":"10.1073\/pnas.0506927102","volume":"102","author":"MD Miller","year":"2005","unstructured":"Miller, M. D. et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. USA 102, 14759\u201314764 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"746_CR49","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.bbrc.2005.04.046","volume":"331","author":"L Ni","year":"2005","unstructured":"Ni, L., Zhao, L., Gao, G. F., Qian, Y. & Tien, P. The antibodies directed against N-terminal heptad-repeat peptide of hRSV fusion protein and its analog-5-Helix inhibit virus infection in vitro. Biochem. Biophys. Res. Commun. 331, 1358\u20131364 (2005).","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"746_CR50","doi-asserted-by":"publisher","first-page":"20278","DOI":"10.1074\/jbc.M301627200","volume":"278","author":"JM Louis","year":"2003","unstructured":"Louis, J. M., Nesheiwat, I., Chang, L., Clore, G. M. & Bewley, C. A. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278, 20278\u201320285 (2003).","journal-title":"J. Biol. Chem."},{"key":"746_CR51","doi-asserted-by":"publisher","first-page":"10655","DOI":"10.1073\/pnas.1004261107","volume":"107","author":"E Bianchi","year":"2010","unstructured":"Bianchi, E. et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc. Natl. Acad. Sci. USA 107, 10655\u201310660 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"746_CR52","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbrc.2010.06.109","volume":"398","author":"Z Qi","year":"2010","unstructured":"Qi, Z. et al. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Biochem. Biophys. Res. Commun. 398, 506\u2013512 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"746_CR53","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.bbrc.2005.05.037","volume":"332","author":"L Ni","year":"2005","unstructured":"Ni, L., Gao, G. F. & Tien, P. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. Biochem. Biophys. Res. Commun. 332, 831\u2013836 (2005).","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"746_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/135965350501000707","volume":"10","author":"L Ni","year":"2005","unstructured":"Ni, L. et al. Design and characterization of human respiratory syncytial virus entry inhibitors. Antivir. Ther. 10, 833\u2013840 (2005).","journal-title":"Antivir. Ther."},{"key":"746_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbrc.2005.02.117","volume":"330","author":"L Ni","year":"2005","unstructured":"Ni, L. et al. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain. Biochem. Biophys. Res. Commun. 330, 39\u201345 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"746_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1087057110393333","volume":"16","author":"W Pang","year":"2011","unstructured":"Pang, W. et al. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure. J. Biomol. Screen. 16, 221\u2013229 (2011).","journal-title":"J. Biomol. Screen"},{"key":"746_CR57","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.it.2020.09.004","volume":"41","author":"E Gavor","year":"2020","unstructured":"Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H. & Sivaraman, J. Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions. Trends Immunol. 41, 1006\u20131022 (2020).","journal-title":"Trends Immunol"},{"key":"746_CR58","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/s41423-020-00528-0","volume":"17","author":"B Liu","year":"2020","unstructured":"Liu, B. et al. Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies. Cell Mol. Immunol. 17, 1098\u20131100 (2020).","journal-title":"Cell Mol. Immunol"},{"key":"746_CR59","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757\u2013773 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"746_CR60","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"746_CR61","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41422-020-0364-z","volume":"30","author":"C Shan","year":"2020","unstructured":"Shan, C. et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Res. 30, 670\u2013677 (2020).","journal-title":"Cell Res."},{"key":"746_CR62","doi-asserted-by":"publisher","first-page":"108837","DOI":"10.1016\/j.celrep.2021.108837","volume":"34","author":"RW Cross","year":"2021","unstructured":"Cross, R. W. et al. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. Cell Rep. 34, 108837 (2021).","journal-title":"Cell Rep."},{"key":"746_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33209-9","volume":"13","author":"C He","year":"2022","unstructured":"He, C. et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat. Commun. 13, 5459 (2022).","journal-title":"Nat. Commun"},{"key":"746_CR64","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2019.11.032","volume":"180","author":"L Mesin","year":"2020","unstructured":"Mesin, L. et al. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. Cell 180, 92\u2013106.e11 (2020).","journal-title":"Cell"},{"key":"746_CR65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.it.2017.04.003","volume":"38","author":"CT Watson","year":"2017","unstructured":"Watson, C. T., Glanville, J. & Marasco, W. A. The individual and population genetics of antibody immunity. Trends Immunol. 38, 459\u2013470 (2017).","journal-title":"Trends Immunol"},{"key":"746_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","volume":"590","author":"L Sanchez-Felipe","year":"2021","unstructured":"Sanchez-Felipe, L. et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590, 320\u2013325 (2021).","journal-title":"Nature"},{"key":"746_CR67","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1007\/s11427-020-1877-4","volume":"64","author":"TZ Song","year":"2021","unstructured":"Song, T. Z., Han, J. B., Yang, X., Li, M. H. & Zheng, Y. T. Tissue distribution of SARS-CoV-2 in non-human primates after combined intratracheal and intranasal inoculation. Sci. China Life Sci. 64, 1792\u20131794 (2021).","journal-title":"Sci. China Life Sci"},{"key":"746_CR68","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-021-03732-8","volume":"596","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature 596, 423\u2013427 (2021).","journal-title":"Nature"},{"key":"746_CR69","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1110\/ps.038273.108","volume":"17","author":"DM Eckert","year":"2008","unstructured":"Eckert, D. M. et al. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci. 17, 2091\u20132100 (2008).","journal-title":"Protein Sci"},{"key":"746_CR70","doi-asserted-by":"publisher","first-page":"25506","DOI":"10.1074\/jbc.M110.101170","volume":"285","author":"X Chen","year":"2010","unstructured":"Chen, X. et al. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J. Biol. Chem. 285, 25506\u201325515 (2010).","journal-title":"J. Biol. Chem."},{"key":"746_CR71","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/v14030597","volume":"14","author":"L Xing","year":"2022","unstructured":"Xing, L. et al. A Five-helix-based SARS-CoV-2 fusion inhibitor targeting heptad repeat 2 domain against SARS-CoV-2 and its variants of concern. Viruses 14, 597 (2022).","journal-title":"Viruses"},{"key":"746_CR72","doi-asserted-by":"publisher","first-page":"e58411","DOI":"10.7554\/eLife.58411","volume":"9","author":"MS Ladinsky","year":"2020","unstructured":"Ladinsky, M. S. et al. Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate. Elife 9, e58411 (2020).","journal-title":"Elife"},{"key":"746_CR73","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","volume":"586","author":"NB Mercado","year":"2020","unstructured":"Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583\u2013588 (2020).","journal-title":"Nature"},{"key":"746_CR74","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","volume":"185","author":"M Gagne","year":"2022","unstructured":"Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185, 1556\u20131571.e18 (2022).","journal-title":"Cell"},{"key":"746_CR75","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"746_CR76","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","volume":"185","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467\u2013484.e15 (2022).","journal-title":"Cell"},{"key":"746_CR77","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"746_CR78","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e13 (2022).","journal-title":"Cell"},{"key":"746_CR79","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1473-3099(22)00422-4","volume":"22","author":"P Arora","year":"2022","unstructured":"Arora, P. et al. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect. Dis. 22, 1117\u20131118 (2022).","journal-title":"Lancet Infect. Dis"},{"key":"746_CR80","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.abq3773","volume":"377","author":"C Dacon","year":"2022","unstructured":"Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728\u2013735 (2022).","journal-title":"Science"},{"key":"746_CR81","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41594-021-00596-4","volume":"28","author":"MM Sauer","year":"2021","unstructured":"Sauer, M. M. et al. Structural basis for broad coronavirus neutralization. Nat. Struct. Mol. Biol. 28, 478\u2013486 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"746_CR82","doi-asserted-by":"publisher","first-page":"eabi9215","DOI":"10.1126\/scitranslmed.abi9215","volume":"14","author":"P Zhou","year":"2022","unstructured":"Zhou, P. et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci. Transl. Med. 14, eabi9215 (2022).","journal-title":"Sci. Transl. Med"},{"key":"746_CR83","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41564-022-01155-3","volume":"7","author":"X Sun","year":"2022","unstructured":"Sun, X. et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat. Microbiol. 7, 1063\u20131074 (2022).","journal-title":"Nat. Microbiol"},{"key":"746_CR84","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.abq2679","volume":"377","author":"JS Low","year":"2022","unstructured":"Low, J. S. et al. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science 377, 735\u2013742 (2022).","journal-title":"Science"},{"key":"746_CR85","doi-asserted-by":"publisher","first-page":"eabn3715","DOI":"10.1126\/scitranslmed.abn3715","volume":"14","author":"KW Ng","year":"2022","unstructured":"Ng, K. W. et al. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci. Transl. Med. 14, eabn3715 (2022).","journal-title":"Sci. Transl. Med."},{"key":"746_CR86","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"746_CR87","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.cell.2022.03.024","volume":"185","author":"A Chandrashekar","year":"2022","unstructured":"Chandrashekar, A. et al. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell 185, 1549\u20131555.e11 (2022).","journal-title":"Cell"},{"key":"746_CR88","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.abf1611","volume":"371","author":"J Qiao","year":"2021","unstructured":"Qiao, J. et al. SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model. Science 371, 1374\u20131378 (2021).","journal-title":"Science"},{"key":"746_CR89","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124\u2013133.e4 (2020).","journal-title":"Cell Host Microbe"},{"key":"746_CR90","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278 (2020).","journal-title":"Science"},{"key":"746_CR91","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"746_CR92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/prep.2001.1603","volume":"25","author":"L Stols","year":"2002","unstructured":"Stols, L. et al. A new vector for high-throughput, ligation-independent cloning encoding a tobacco etch virus protease cleavage site. Protein Expr. Purif. 25, 8\u201315 (2002).","journal-title":"Protein Expr. Purif."},{"key":"746_CR93","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. [20] Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol"},{"key":"746_CR94","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"746_CR95","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"746_CR96","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"746_CR97","doi-asserted-by":"publisher","first-page":"503","DOI":"10.24272\/j.issn.2095-8137.2020.202","volume":"41","author":"TZ Song","year":"2020","unstructured":"Song, T. Z. et al. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zool. Res. 41, 503\u2013516 (2020).","journal-title":"Zool. Res."},{"key":"746_CR98","doi-asserted-by":"publisher","first-page":"e20201181","DOI":"10.1084\/jem.20201181","volume":"217","author":"F Schmidt","year":"2020","unstructured":"Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).","journal-title":"J. Exp. Med."},{"key":"746_CR99","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15, 3699\u20133715 (2020).","journal-title":"Nat. Protoc."}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00746-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00746-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00746-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:07:28Z","timestamp":1669900048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41422-022-00746-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":99,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1038\/s41422-022-00746-3","relation":{},"ISSN":["1748-7838"],"issn-type":[{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.T.Z., W.P., Y.L., W.Q.H., X.Y.H., R.H.L., and F.S. are listed as inventors on the Chinese patent of \u201cA recombinant fusion protein derived from HR domains in S2 subunit of SARS-CoV-2 and its application (authorization No.: ZL202111167024.2)\u201d related to this work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}